<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04975724</url>
  </required_header>
  <id_info>
    <org_study_id>QQ05.16.02</org_study_id>
    <nct_id>NCT04975724</nct_id>
  </id_info>
  <brief_title>Safety of Liposom With Citalopram in Elderly Patients With Major Depressive Disorder</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Assess Safety and Effectiveness of Liposom in Enhance and Speed up Response With Citalopram in Elderly Patients Suffering From Major Depressive Disorder (MDD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fidia Farmaceutici s.p.a.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fidia Farmaceutici s.p.a.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if Liposom Forte will enhance the response to&#xD;
      antidepressant therapy with citalopram in elderly patients suffering from Major Depressive&#xD;
      Disorder (MDD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The effects of phospholipid liposomes when associated with antidepressant drugs are very&#xD;
      interesting. In addition to an improvement of somatic symptoms of depression, measured with&#xD;
      the Hamilton Rate Scale for Depression, liposomes are able to reduce the latency of onset of&#xD;
      the antidepressant activity of drugs like amitriptyline, clomipramine, and trazodone. These&#xD;
      results indicate that phospholipids can be used as an adjuvant to antidepressant therapy,&#xD;
      also allowing specific antidepressant drug dose reduction. Thus, the hypothesis is that&#xD;
      combination therapy would not only lead to greater efficacy, but also to a more rapid onset&#xD;
      of therapeutic response. The addition of Liposom Forte may be clinically important since it&#xD;
      may ensure the use of lower citalopram doses, thereby reducing the risk of adverse events,&#xD;
      and this may prove to be important, especially in elderly people.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 18, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of depressive symptoms atV5(day30)as change from baseline withHamiltonRatingScaleforDepression(HAM-D).HAM-D has21items,scoring based on the first17.9items from0=not present;to4=severe.8 from0-2.Scores from the first17items summed:≥16=MajorDep</measure>
    <time_frame>Day 30 (V5)</time_frame>
    <description>The purpose of this study is to determine if Liposom Forte will enhance the response to antidepressant therapy with citalopram in elderly patients suffering from Major Depressive Disorder (MDD).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of latency of antidepressant therapy with citalopram. It will be evaluated at V2,V3,V4 andV5 using HAM-D.Latency time:the time from baseline to response (a≥50% improvement in HAM-D score vs baseline)</measure>
    <time_frame>From baseline through 30 days follow-up (V5)</time_frame>
    <description>Determine if Liposom Forte will speed up response to antidepressant therapy with citalopram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ClinicalGlobalImpression as change from baseline withCGI up toV8Day90.CGI:7point scale clinician-rated(severity of illness)from1(normal)to7(severely ill).CGI score from1(very much improved)to7(very much worse).Treatment response consider efficacy andAEs</measure>
    <time_frame>From baseline through 90 days follow-up (V8)</time_frame>
    <description>Determine the Clinical Global Impression to treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of study treatments by tracking number and type of adverse events at each visit, up to V8 (Day 90)</measure>
    <time_frame>From baseline through 90 days follow-up (V8)</time_frame>
    <description>To assess the safety of study treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of study treatments by tracking, up to V8 (Day 90), 12-lead ECG, QTcF interval (Fridericia equation) will be measured</measure>
    <time_frame>From baseline to Day 14 (V3) and Day 90 (V8)</time_frame>
    <description>To assess the safety of study treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of study treatments by tracking, up to V8 (Day 90), blood pressure measurements in mmHg</measure>
    <time_frame>From baseline through 90 days follow-up (V8)</time_frame>
    <description>To assess the safety of study treatments tracking blood pressure measurement in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of study treatments by tracking, up to V8 (Day 90), heart rate measurements in bpm</measure>
    <time_frame>From baseline through 90 days follow-up (V8)</time_frame>
    <description>To assess the safety of study treatments tracking heart rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of study treatments by tracking, up to V8 (Day 90), oxygen saturation measurements in percentage with a pulse oximetry device</measure>
    <time_frame>From baseline through 90 days follow-up (V8)</time_frame>
    <description>To assess the safety of study treatments tracking oxygen saturation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of depressive symptoms during the entire study as change from baseline therapy with citalopram over the entire study</measure>
    <time_frame>From baseline through 90 days follow-up (V8)</time_frame>
    <description>Change of depressive symptoms will be evaluated over the entire study as change from baseline using the HAM-D (Hamilton Rating Scale for Depression). The score is based on the first 17 items: nine items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Eight are scored from 0-2. The score is summed and patients are categorized as follows: 0-7 = No depression 8-15 = Minor Depression&#xD;
≥ 16 = Major Depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients responders at V2, V3, V4 and V5. ≥50% improvement in HAM-D score vs baseline will be considered as responder.</measure>
    <time_frame>From baseline through 30 days follow-up (V5)</time_frame>
    <description>determine if Liposom Forte will speed up response to antidepressant therapy with citalopram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of depressive symptoms as change from baseline using GeriatricDepressionScale(GDS-15) at each visit, up to V8(Day90). GDS:brief questionnaire:15questions with options yes or no in reference to how patients felt on the day of administration</measure>
    <time_frame>From baseline through 90 days follow-up (V8)</time_frame>
    <description>Change of depressive symptoms will be evaluated over the entire study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Group A Liposom Forte</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liposom Forte (2 ampoules of 28mg/2 ml) for 30 days + citalopram (10mg) for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (2 ampoules of 2 ml) for 30 days + citalopram (10mg) for 90 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposom Forte</intervention_name>
    <description>Liposom Forte 28mg/2ml solution for injection contains a mixture of purified hypothalamic phospholipids (PLs) from swine brains. The key components of the phospholipid mixture are phosphatidylcholine (PC), phosphatidylethanolamine (PE) and phosphatidylserine (PS).</description>
    <arm_group_label>Group A Liposom Forte</arm_group_label>
    <other_name>Liposom</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citalopram</intervention_name>
    <description>The medicinal product Citalopram Aurobindo contains citalopram as active ingredient available on the market in 20 mg film coated tablets. The tablets are divisible in two equal part of 10 mg as reported in the SmPC</description>
    <arm_group_label>Group A Liposom Forte</arm_group_label>
    <arm_group_label>Group B Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Meets DSM-V criteria for major depressive disorder&#xD;
&#xD;
          2. Score of ≥ 16 in the HAM-D&#xD;
&#xD;
          3. Score of ≥ 23 on the Mini-Mental State Exam (MMSE-2)&#xD;
&#xD;
          4. Aged ≥ 65 and &lt; 85 years&#xD;
&#xD;
          5. Patients able to understand the study procedures and to comply with protocol&#xD;
             requirements&#xD;
&#xD;
          6. Patients legally able to give written informed consent to the trial (signed and dated&#xD;
             by the subject)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any contraindication for treatment or intolerance to Liposom Forte or citalopram&#xD;
&#xD;
          2. Congenital long QT syndrome, bradycardia, recent acute myocardial infarction,&#xD;
             uncompensated heart failure or concomitant use of drugs that prolong the QT interval&#xD;
&#xD;
          3. History of psychiatric disorder other than major depressive disorder, including&#xD;
             history of substance use disorder&#xD;
&#xD;
          4. Presence of psychotic symptoms, even if they are not sufficient to make diagnosis of a&#xD;
             mental disorder&#xD;
&#xD;
          5. Severe organic disease (e.g., major surgery, metastatic cancer, stroke, delirium,&#xD;
             severe neurological disorder, heart attack, chronic heart failure, asthma, severe&#xD;
             cardio circulatory disorders)&#xD;
&#xD;
          6. Diabetes Mellitus type I and II&#xD;
&#xD;
          7. Acute suicidal or violent behaviour or history of suicide attempt within the year&#xD;
             prior to study entry or current suicidal ideation&#xD;
&#xD;
          8. Treated with long acting injectable (LAI) antipsychotics within 6 months prior to&#xD;
             study entry&#xD;
&#xD;
          9. Treated with any antipsychotics, antidepressant, food supplements or over-the-counter&#xD;
             CNS-active medications (e.g, St. John's Wort, melatonin, Selective Serotonin Reuptake&#xD;
             Inhibitors [SSRIs], Serotonin and norepinephrine reuptake inhibitors [SNRIs],&#xD;
             Monoamine-Oxidase Inhibitors [MAOIs], or other antidepressants) within 4 weeks prior&#xD;
             to the first administration of study medication&#xD;
&#xD;
         10. Ongoing or planned psychotherapy or other psychological treatment during the study&#xD;
             period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicola Giordan</last_name>
    <role>Study Director</role>
    <affiliation>Fidia Farmaceutici s.p.a.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicola Giordan, Dr</last_name>
    <phone>0039 049 8232512</phone>
    <email>ngiordan@fidiapharma.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>UOC Geriatria e Lungodegenza Geriatrica PO San Filippo e Nicola di Avezzano - ASL1 Avezzano Sulmona L'aquila</name>
      <address>
        <city>Avezzano</city>
        <zip>67051</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>UO Psichiatria - ASST Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Unità Operativa di Psichiatria, Azienda Ospedaliero-Universitaria Mater Domini</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ambulatorio Psichiatrico, UOC Psichiatria Presidio Ospedaliero di Codogno - ASST Lodi</name>
      <address>
        <city>Codogno</city>
        <zip>26845</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>SOD Geriatria-UTIG Azienda Ospedaliero-Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Servizio Psichiatrico di Diagnosi e Cura (SPDC) Foggia, Ospedali Riuniti di Foggia</name>
      <address>
        <city>Foggia</city>
        <zip>71122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Servizio Psichiatrico di Diagnosi e Cura (SPDC) - ASL3 Ente Ospedaliero Ospedali Galliera</name>
      <address>
        <city>Genova</city>
        <zip>16128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ambulatorio Clinica Psichiatrica, Ospedale Policlinico S. Martino</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>UOC Geriatria PO San Salvatore - ASL1 Avezzano Sulmona L'Aquila</name>
      <address>
        <city>L'Aquila</city>
        <zip>67100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>SPDC Ospedale Fatebenefratell, UOC Psichiatria 1 ASST Fatebenefratelli Sacco</name>
      <address>
        <city>Milano</city>
        <zip>20121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio Mencacci</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Depressione Anziani S.C. Psichiatria 51, ASST Santi Paolo e Carlo - Presidio San Paolo</name>
      <address>
        <city>Milano</city>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone Cavallotti</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UO Medicina a indirizzo geriatrico ASST degli Spedali Civili di Brescia - Ospedale di Montichiari</name>
      <address>
        <city>Montichiari</city>
        <zip>25018</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>U.O. Psichiatria 2 Universitaria AOU Pisana - P.O. Santa Chiara</name>
      <address>
        <city>Pisa</city>
        <zip>56100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>UOC Psichiatria - Azienda Ospedaliero-Universitaria Sant'Andrea</name>
      <address>
        <city>Roma</city>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Salute Mentale - UO Psichiatria Ambito Territoriale Est Ospedale San Lorenzo Borgo Valsugana - Azienda Provinciale per i Servizi Sanitari di Trento</name>
      <address>
        <city>Trento</city>
        <zip>38151</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Psichiatrica, Azienda Sanitaria Universitaria Integrata di Udine</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matteo Balestrieri</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 2, 2020</study_first_submitted>
  <study_first_submitted_qc>July 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2021</study_first_posted>
  <last_update_submitted>July 14, 2021</last_update_submitted>
  <last_update_submitted_qc>July 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

